2seventy bio
company
About
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.
- 251 - 500
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $20M
- Industries
- Biotechnology,Genetics,Health Care,Therapeutics
- Founded date
- Jan 1, 2021
- Number Of Employee
- 251 - 500
- Operating Status
- Active
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline.
It was established in Cambridge, Massachusetts in 2021.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$190M
2seventy bio has raised a total of
$190M
in funding over 2 rounds. Their latest funding was raised on
Jan 6, 2023 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 6, 2023 | Post-IPO Equity | $20M | 1 |
Regeneron
|
— | Detail |
| Mar 16, 2022 | Post-IPO Equity | $170M | 2 | — | — | Detail |
Investments
Number of Investments
Number of Lead Investments
5
0
2seventy bio has made 5 investments. Their most recent investment was on
Feb 15, 2022, when Cohere raised $159M.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Feb 15, 2022
Cohere
|
Series B | $159M | Artificial Intelligence | — |
|
Jan 17, 2022
Wayve
|
Series B | $200M | Artificial Intelligence | — |
|
Sep 7, 2021
Cohere
|
Series A | $40M | Artificial Intelligence | — |
|
Jun 8, 2021
Waabi
|
Series A | $100M | Artificial Intelligence | — |
|
Jul 1, 2019
Wayve
|
Series A | $20M | Artificial Intelligence | — |
Investors
Number of Lead Investors
Number of Investors
1
3
2seventy bio is funded by 3 investors.
Regeneron
and Newtyn Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Regeneron
|
Yes | Post-IPO Equity |
|
|
— | Post-IPO Equity |
|
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
